Transforming properties of 8p11-12 amplified genes in human breast cancer.
about
ZNF703 gene amplification at 8p12 specifies luminal B breast cancerHistone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and preventionConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.Identification and functional analysis of 9p24 amplified genes in human breast cancer.The pur protein family: genetic and structural features in development and disease.Fibroblast growth factor receptors in breast cancer.Neural crest specification and migration independently require NSD3-related lysine methyltransferase activity.Genetic alterations of histone lysine methyltransferases and their significance in breast cancerIntra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible miceA novel ER-microtubule-binding protein, ERLIN2, stabilizes Cyclin B1 and regulates cell cycle progression.Affinity capture and identification of host cell factors associated with hepatitis C virus (+) strand subgenomic RNAHigh expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancerEndoplasmic reticulum factor ERLIN2 regulates cytosolic lipid content in cancer cellsComprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck.Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.Development and optimization of piperidyl-1,2,3-triazole ureas as selective chemical probes of endocannabinoid biosynthesis.Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer.An open and shut case for the role of NSD proteins as oncogenes.A global assessment of cancer genomic alterations in epigenetic mechanisms.The NSD family of protein methyltransferases in human cancer.Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin.H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor developmentDysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas.An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.The PWWP domain of the human oncogene WHSC1L1/NSD3 induces a metabolic shift toward fermentation.Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3.Backbone resonance assignments for the SET domain of human methyltransferase NSD3 in complex with its cofactor.FTO Gene Affects Obesity and Breast Cancer Through Similar Mechanisms: A New Insight into the Molecular Therapeutic Targets.Current Challenges and Opportunities in Treating Glioblastoma.Identification of a peptide inhibitor for the histone methyltransferase WHSC1.
P2860
Q24293333-EBE39F61-CEA7-4CE2-AAEB-CE91243730B2Q26994739-70A76A7F-5116-4DEF-B4D0-FF56E9F6213EQ27853093-FDCFB4E7-0D6D-443E-8AAA-F0065CA605A4Q30586112-AF6C41D4-1E18-406A-8CAA-0439B86F445DQ34191958-6E05DC8E-6B24-4B96-A53C-924520EA18BBQ34423435-DC746232-570B-426C-96C2-2CEE23422B35Q34556066-441A4A3E-C3B6-49FD-9E10-A28190BB3D8AQ34680417-94FBAFA7-4EB7-4740-BCB0-23CEAD6C0267Q35273743-77D8B2A5-19C0-465F-A433-10029F6962CCQ35633666-2661260E-0B1E-425C-A0CB-82FDF099D9EDQ35932114-BC1F22CD-D63E-4D34-9631-B3190920E234Q36395823-C3959380-5500-473B-81EA-1D0385008A1CQ36812809-0950D11D-B817-41C8-858A-053094752CDBQ36882828-E2B7C3AD-5E47-41C7-87D6-FC4A150A2EF0Q36910780-D5FE9AFB-01BD-4CCC-886A-9A8760531072Q37236234-2A3F50CD-7593-4A44-859D-2C7464018E8FQ37250797-1F83853D-D544-4D03-9F74-21096C671546Q37338907-5A07F7EA-9EC5-4844-A3DE-6B9CC5CB0E3CQ37520610-DEC0B13C-0B59-4DA1-981A-59BD39B8D71CQ37600589-3DBBD394-D6ED-4C55-8A2C-5BBF63FB1ADCQ37698548-2DB3E17F-8D06-4FF4-AA89-448DAB0B74BAQ37706554-A27AC91B-1314-429D-8AAB-2A0FE0BB1A15Q38437979-B8D7A348-2093-4269-B65A-73BAAC316D37Q38446450-C736EB17-F669-4D6C-8E6B-46DB626E1F8CQ38459795-007C9E04-9575-4D90-921F-DB2610715A39Q38594002-7AF5FF10-9E72-4E14-8078-9CBE0D799E02Q38637914-5FD8F8F3-5658-4CB8-A9D0-9AF0D90CA2B1Q38829055-077065FC-0F29-44A6-9465-43CCD1042947Q38975402-77B07D67-DD98-4ECC-A0A8-D33DEEC48C7EQ39134084-4AF5D3FB-90DE-47C5-A16D-CD05AF72CC5EQ40058161-584D005B-1449-481B-8011-33F6BF1FEBBFQ40417660-E8244B90-4D6B-44B7-B7EC-666DF3A8670DQ41553291-86979087-4D29-48F1-946D-97E8B66FA4DEQ42535435-55B599F7-7898-4F75-90C7-73AE53F20375Q47681326-6A709B6A-CD62-4D95-828B-CF0698FEDDE0Q47769849-E6836E5A-A577-400D-B2D0-5F06D312DC81Q48238344-C07F6EE3-F51B-4E28-A872-96F5007D6824Q50002067-FC7ADE58-7BF0-4EBE-A9B2-D50888C005AFQ52579808-60DEA23B-46BA-41F9-A2D7-8D194AA33A46Q55104676-B3793B19-04EF-4F43-8BA3-78C9784BE228
P2860
Transforming properties of 8p11-12 amplified genes in human breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@ast
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@en
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@nl
type
label
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@ast
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@en
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@nl
prefLabel
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@ast
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@en
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@nl
P2093
P2860
P1433
P1476
Transforming properties of 8p11-12 amplified genes in human breast cancer.
@en
P2093
Aliccia Bollig-Fischer
Craig N Giroux
Stephen P Ethier
Zeng-Quan Yang
P2860
P304
P356
10.1158/0008-5472.CAN-10-1013
P407
P577
2010-10-12T00:00:00Z